NeoRecormon

Country: Kesatuan Eropah

Bahasa: Inggeris

Sumber: EMA (European Medicines Agency)

Beli sekarang

Risalah maklumat Risalah maklumat (PIL)
15-03-2023
Ciri produk Ciri produk (SPC)
15-03-2023
Laporan Penilaian Awam Laporan Penilaian Awam (PAR)
03-12-2015

Bahan aktif:

epoetin beta

Boleh didapati daripada:

Roche Registration GmbH

Kod ATC:

B03XA01

INN (Nama Antarabangsa):

epoetin beta

Kumpulan terapeutik:

Antianemic preparations

Kawasan terapeutik:

Kidney Failure, Chronic; Anemia; Cancer; Blood Transfusion, Autologous

Tanda-tanda terapeutik:

Treatment of symptomatic anaemia associated with chronic renal failure (CRF) in adult and paediatric patients;treatment of symptomatic anaemia in adult patients with non-myeloid malignancies receiving chemotherapy;increasing the yield of autologous blood from patients in a pre-donation programme. Its use in this indication must be balanced against the reported increased risk of thromboembolic events. Treatment should only be given to patients with moderate anaemia (Hb 10 - 13 g/dl [6.21 - 8.07 mmol/l], no iron deficiency) if blood conserving procedures are not available or insufficient when the scheduled major elective surgery requires a large volume of blood (4 or more units of blood for females or 5 or more units for males).

Ringkasan produk:

Revision: 33

Status kebenaran:

Authorised

Tarikh kebenaran:

1997-07-16

Risalah maklumat

                                48
B. PACKAGE LEAFLET
49
PACKAGE LEAFLET: INFORMATION FOR THE USER
NEORECORMON 500 IU
NEORECORMON 2000 IU
NEORECORMON 3000 IU
NEORECORMON 4000 IU
NEORECORMON 5000 IU
NEORECORMON 6000 IU
NEORECORMON 10,000 IU
NEORECORMON 20,000 IU
NEORECORMON 30,000 IU
SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE
epoetin beta
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
•
Keep this leaflet. You may need to read it again.
•
If you have any further questions, ask your doctor or pharmacist.
•
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs or illness are the same as yours.
•
If you get any side effects, talk to your doctor or pharmacist. This
includes any possible side
effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What NeoRecormon is and what it is used for
2.
What you need to know before you use NeoRecormon
3.
How to use NeoRecormon
4.
Possible side effects
5.
How to store NeoRecormon
6.
Content of the pack and other information
1.
WHAT NEORECORMON IS AND WHAT IT IS USED FOR
NeoRecormon is a clear, colourless solution for injection under the
skin
_(subcutaneously)_
or into a
vein
_(intravenously). _
It contains a hormone called
_epoetin beta_
, which stimulates the production of red
blood cells. Epoetin beta is produced by a specialised genetic
technology and works in exactly the
same way as the natural hormone erythropoietin.
You must talk to your doctor if you do not feel better or if you feel
worse.
NeoRecormon is indicated for:
•
TREATING SYMPTOMATIC ANAEMIA CAUSED BY CHRONIC KIDNEY DISEASE
(renal anaemia) in patients
on dialysis, or not yet on dialysis.
•
PREVENTING ANAEMIA IN PREMATURE INFANTS
(weighing 750 to 1500 g and born at less than
34 weeks).
•
TREATING ANAEMIA WITH RELATED SYMPTOMS IN ADULT CANCER PATIENTS
RECEIVING CHEMOTHERAPY
•
TREATING PEOPLE DONATING THEIR OWN BLOOD BEFORE SURGERY.
The injections of epoetin beta will
increas
                                
                                Baca dokumen lengkap
                                
                            

Ciri produk

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
NeoRecormon 500 IU solution for injection in pre-filled syringe
NeoRecormon 2000 IU solution for injection in pre-filled syringe
NeoRecormon 3000 IU solution for injection in pre-filled syringe
NeoRecormon 4000 IU solution for injection in pre-filled syringe
NeoRecormon 5000 IU solution for injection in pre-filled syringe
NeoRecormon 6000 IU solution for injection in pre-filled syringe
NeoRecormon 10,000 IU solution for injection in pre-filled syringe
NeoRecormon 20,000 IU solution for injection in pre-filled syringe
NeoRecormon 30,000 IU solution for injection in pre-filled syringe
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
NeoRecormon 500 IU solution for injection in pre-filled syringe
One pre-filled syringe with 0.3 ml solution for injection contains 500
international units (IU)
corresponding to 4.15 micrograms epoetin beta* (recombinant human
erythropoietin).
One ml solution for injection contains 1667 IU epoetin beta.
NeoRecormon 2000 IU solution for injection in pre-filled syringe
One pre-filled syringe with 0.3 ml solution for injection contains
2000 international units (IU)
corresponding to 16.6 micrograms epoetin beta* (recombinant human
erythropoietin).
One ml solution for injection contains 6667 IU epoetin beta.
NeoRecormon 3000 IU solution for injection in pre-filled syringe
One pre-filled syringe with 0.3 ml solution for injection contains
3000 international units (IU)
corresponding to 24.9 micrograms epoetin beta* (recombinant human
erythropoietin).
One ml solution for injection contains 10,000 IU epoetin beta.
NeoRecormon 4000 IU solution for injection in pre-filled syringe
One pre-filled syringe with 0.3 ml solution for injection contains
4000 international units (IU)
corresponding to 33.2 micrograms epoetin beta* (recombinant human
erythropoietin).
One ml solution for injection contains 13,333 IU epoetin beta.
NeoRecormon 5000 IU solution for injection in pre-filled syringe
One pre-filled syringe with 0.3 ml solution
                                
                                Baca dokumen lengkap
                                
                            

Dokumen dalam bahasa lain

Risalah maklumat Risalah maklumat Bulgaria 15-03-2023
Ciri produk Ciri produk Bulgaria 15-03-2023
Laporan Penilaian Awam Laporan Penilaian Awam Bulgaria 03-12-2015
Risalah maklumat Risalah maklumat Sepanyol 15-03-2023
Ciri produk Ciri produk Sepanyol 15-03-2023
Laporan Penilaian Awam Laporan Penilaian Awam Sepanyol 03-12-2015
Risalah maklumat Risalah maklumat Czech 15-03-2023
Ciri produk Ciri produk Czech 15-03-2023
Laporan Penilaian Awam Laporan Penilaian Awam Czech 03-12-2015
Risalah maklumat Risalah maklumat Denmark 15-03-2023
Ciri produk Ciri produk Denmark 15-03-2023
Laporan Penilaian Awam Laporan Penilaian Awam Denmark 03-12-2015
Risalah maklumat Risalah maklumat Jerman 15-03-2023
Ciri produk Ciri produk Jerman 15-03-2023
Laporan Penilaian Awam Laporan Penilaian Awam Jerman 03-12-2015
Risalah maklumat Risalah maklumat Estonia 15-03-2023
Ciri produk Ciri produk Estonia 15-03-2023
Laporan Penilaian Awam Laporan Penilaian Awam Estonia 03-12-2015
Risalah maklumat Risalah maklumat Greek 15-03-2023
Ciri produk Ciri produk Greek 15-03-2023
Laporan Penilaian Awam Laporan Penilaian Awam Greek 03-12-2015
Risalah maklumat Risalah maklumat Perancis 15-03-2023
Ciri produk Ciri produk Perancis 15-03-2023
Laporan Penilaian Awam Laporan Penilaian Awam Perancis 03-12-2015
Risalah maklumat Risalah maklumat Itali 15-03-2023
Ciri produk Ciri produk Itali 15-03-2023
Laporan Penilaian Awam Laporan Penilaian Awam Itali 03-12-2015
Risalah maklumat Risalah maklumat Latvia 15-03-2023
Ciri produk Ciri produk Latvia 15-03-2023
Laporan Penilaian Awam Laporan Penilaian Awam Latvia 03-12-2015
Risalah maklumat Risalah maklumat Lithuania 15-03-2023
Ciri produk Ciri produk Lithuania 15-03-2023
Laporan Penilaian Awam Laporan Penilaian Awam Lithuania 03-12-2015
Risalah maklumat Risalah maklumat Hungary 15-03-2023
Ciri produk Ciri produk Hungary 15-03-2023
Laporan Penilaian Awam Laporan Penilaian Awam Hungary 03-12-2015
Risalah maklumat Risalah maklumat Malta 15-03-2023
Ciri produk Ciri produk Malta 15-03-2023
Laporan Penilaian Awam Laporan Penilaian Awam Malta 03-12-2015
Risalah maklumat Risalah maklumat Belanda 15-03-2023
Ciri produk Ciri produk Belanda 15-03-2023
Laporan Penilaian Awam Laporan Penilaian Awam Belanda 03-12-2015
Risalah maklumat Risalah maklumat Poland 15-03-2023
Ciri produk Ciri produk Poland 15-03-2023
Laporan Penilaian Awam Laporan Penilaian Awam Poland 03-12-2015
Risalah maklumat Risalah maklumat Portugis 15-03-2023
Ciri produk Ciri produk Portugis 15-03-2023
Laporan Penilaian Awam Laporan Penilaian Awam Portugis 03-12-2015
Risalah maklumat Risalah maklumat Romania 15-03-2023
Ciri produk Ciri produk Romania 15-03-2023
Laporan Penilaian Awam Laporan Penilaian Awam Romania 03-12-2015
Risalah maklumat Risalah maklumat Slovak 15-03-2023
Ciri produk Ciri produk Slovak 15-03-2023
Laporan Penilaian Awam Laporan Penilaian Awam Slovak 03-12-2015
Risalah maklumat Risalah maklumat Slovenia 15-03-2023
Ciri produk Ciri produk Slovenia 15-03-2023
Laporan Penilaian Awam Laporan Penilaian Awam Slovenia 03-12-2015
Risalah maklumat Risalah maklumat Finland 15-03-2023
Ciri produk Ciri produk Finland 15-03-2023
Laporan Penilaian Awam Laporan Penilaian Awam Finland 03-12-2015
Risalah maklumat Risalah maklumat Sweden 15-03-2023
Ciri produk Ciri produk Sweden 15-03-2023
Laporan Penilaian Awam Laporan Penilaian Awam Sweden 03-12-2015
Risalah maklumat Risalah maklumat Norway 15-03-2023
Ciri produk Ciri produk Norway 15-03-2023
Risalah maklumat Risalah maklumat Iceland 15-03-2023
Ciri produk Ciri produk Iceland 15-03-2023
Risalah maklumat Risalah maklumat Croat 15-03-2023
Ciri produk Ciri produk Croat 15-03-2023
Laporan Penilaian Awam Laporan Penilaian Awam Croat 03-12-2015

Cari amaran yang berkaitan dengan produk ini

Lihat sejarah dokumen